Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript
Operator: Welcome to the Calliditas Therapeutics Q4 2023 Report. For the first part of the conference call, the participants will be in listen-only mode.
Calliditas Therapeutics Ab (CALT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 750,000 | $16,237,500 | 0.44% | |
| 2. | Ironwood Investment Management Warren Isabelle | 25,511 | $535,986 | +1% | 0.26% |
| 3. | Citadel Investment Group Ken Griffin | 14,594 | $315,960 | +1665% | 0% |
| 4. | 9,600 | $207,840 | -4% | 0% | |
| 5. | 1,500 | $32,475 | -84% | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 50,550 | $1,301,157 | 0% | |
| 2. | 31,600 | $814,332 | 0% | |
| 3. | 14,400 | $371,088 | 0% | |
| 4. | 9,412 | $242,547 | 0% | |
| 5. | 2,000 | $51,540 | 0% |
News See All
Is CALT A Good Stock To Buy Now?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
Billionaire Hedge Funds
